NEW YORK (GenomeWeb News) – Decode Genetics today announced a research collaboration with Pfizer targeting sequence variants associated with specific clinical phenotypes related to systemic lupus erythematosis.
During the next 18 months, the firms will analyze the genomes of patients to discover sequence variants that could shed light on drug targets and lead to new drug targets.
Kari Stefansson, founder and CEO of Decode, based in Reykjavik, Iceland, said in a statement that the company's research platform "allows us to understand the genetic basis of disease and modifiers of clinical phenotypes in actual patient populations; by doing so, we can rapidly move from targets to patient stratification and from there to companion diagnostics."
Financial and other terms of the deal were not disclosed.